Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Shares Bought by Allianz Asset Management GmbH

Allianz Asset Management GmbH grew its stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 306.1% during the 4th quarter, HoldingsChannel reports. The firm owned 108,871 shares of the biopharmaceutical company’s stock after buying an additional 82,065 shares during the quarter. Allianz Asset Management GmbH’s holdings in Alnylam Pharmaceuticals were worth $25,618,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also made changes to their positions in ALNY. Ieq Capital LLC grew its position in shares of Alnylam Pharmaceuticals by 825.5% during the 4th quarter. Ieq Capital LLC now owns 38,806 shares of the biopharmaceutical company’s stock valued at $9,131,000 after acquiring an additional 34,613 shares during the period. Venturi Wealth Management LLC boosted its position in Alnylam Pharmaceuticals by 6,200.0% during the fourth quarter. Venturi Wealth Management LLC now owns 252 shares of the biopharmaceutical company’s stock worth $59,000 after purchasing an additional 248 shares in the last quarter. Truist Financial Corp grew its holdings in Alnylam Pharmaceuticals by 136.6% in the fourth quarter. Truist Financial Corp now owns 4,398 shares of the biopharmaceutical company’s stock valued at $1,035,000 after purchasing an additional 2,539 shares during the period. CIBC Asset Management Inc increased its position in shares of Alnylam Pharmaceuticals by 14.5% in the fourth quarter. CIBC Asset Management Inc now owns 5,134 shares of the biopharmaceutical company’s stock valued at $1,208,000 after buying an additional 651 shares in the last quarter. Finally, Sanctuary Advisors LLC increased its position in shares of Alnylam Pharmaceuticals by 7.8% in the fourth quarter. Sanctuary Advisors LLC now owns 4,915 shares of the biopharmaceutical company’s stock valued at $1,157,000 after buying an additional 357 shares in the last quarter. Institutional investors and hedge funds own 92.97% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts recently issued reports on the stock. Piper Sandler reissued an “overweight” rating and issued a $296.00 price target on shares of Alnylam Pharmaceuticals in a research note on Monday, November 18th. Canaccord Genuity Group increased their price objective on shares of Alnylam Pharmaceuticals from $384.00 to $385.00 and gave the company a “buy” rating in a report on Tuesday, February 18th. Royal Bank of Canada reissued an “outperform” rating and set a $300.00 target price on shares of Alnylam Pharmaceuticals in a research note on Tuesday, February 11th. HC Wainwright increased their price objective on Alnylam Pharmaceuticals from $400.00 to $500.00 and gave the company a “buy” rating in a research note on Monday. Finally, Chardan Capital reaffirmed a “buy” rating and set a $300.00 price objective on shares of Alnylam Pharmaceuticals in a research note on Friday, November 1st. One equities research analyst has rated the stock with a sell rating, six have given a hold rating and nineteen have assigned a buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $303.83.

Alnylam Pharmaceuticals Stock Performance

NASDAQ:ALNY opened at $248.94 on Tuesday. The stock has a market capitalization of $32.23 billion, a P/E ratio of -114.72 and a beta of 0.35. The company has a debt-to-equity ratio of 15.27, a quick ratio of 2.71 and a current ratio of 2.78. Alnylam Pharmaceuticals, Inc. has a fifty-two week low of $141.98 and a fifty-two week high of $304.39. The company has a 50 day moving average price of $254.24 and a 200 day moving average price of $262.90.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its quarterly earnings results on Thursday, February 13th. The biopharmaceutical company reported ($0.65) EPS for the quarter, missing the consensus estimate of ($0.62) by ($0.03). Equities research analysts forecast that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current year.

Insider Buying and Selling at Alnylam Pharmaceuticals

In other Alnylam Pharmaceuticals news, CEO Yvonne Greenstreet sold 1,213 shares of the stock in a transaction that occurred on Friday, February 14th. The shares were sold at an average price of $255.17, for a total transaction of $309,521.21. Following the sale, the chief executive officer now directly owns 81,526 shares in the company, valued at $20,802,989.42. This represents a 1.47 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CMO Pushkal Garg sold 52,592 shares of the firm’s stock in a transaction that occurred on Monday, January 27th. The shares were sold at an average price of $285.00, for a total transaction of $14,988,720.00. Following the completion of the transaction, the chief marketing officer now directly owns 11,989 shares of the company’s stock, valued at $3,416,865. This represents a 81.44 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 72,986 shares of company stock valued at $20,397,849 in the last three months. 1.50% of the stock is owned by corporate insiders.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.